Tag: options

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the “Grant Date”), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025.

MARKHAM, Ontario, July 03, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2025 second quarter results after market close on Tuesday, August 12, 2025. Nitin Jain, President and Chief Executive Officer, and David Hung, Chief Financial Officer and Executive Vice President, Investments, will host a conference call for the investment community the following day, Wednesday, August 13, 2025 at 10:00 a.m. (ET).